Zura(US:ZURA)2025-05-08 10:50Financial Performance - Zura Bio reported a net loss of $17.4 million, or $0.19 per share, for Q1 2025, compared to a net loss of $7.7 million, or $0.02 per share, in Q1 2024[12][22]. - Total operating expenses for Q1 2025 were $19.3 million, compared to $8.4 million in Q1 2024[22]. - Zura Bio's accumulated deficit increased to $173.3 million as of March 31, 2025, compared to $155.9 million at the end of 2024[20]. Research and Development - Research and Development (R&D) expenses increased to $10.5 million in Q1 2025 from $3.6 million in Q1 2024, primarily due to higher contract research organization costs and manufacturing costs[10]. - The Phase 2 TibuSURE trial for tibulizumab in adults with systemic sclerosis (SSc) is ongoing, with preparations for a second Phase 2 trial in hidradenitis suppurativa (HS) expected to initiate in Q2 2025[3][4][7]. - The company is exploring the potential of crebankitug in immune-mediated diseases and evaluating torudokimab for inflammatory and respiratory diseases[5][6]. Administrative Expenses - General and Administrative (G&A) expenses rose to $8.8 million in Q1 2025, up from $4.8 million in Q1 2024, driven by increased compensation costs and professional fees[11]. Cash Position - As of March 31, 2025, Zura Bio had cash and cash equivalents of $170.6 million, with a cash runway anticipated through 2027[9][7]. - The total assets of Zura Bio as of March 31, 2025, were $172.5 million, down from $179.5 million as of December 31, 2024[20]. Organizational Changes - The company appointed Kate Dingwall as Senior Vice President of Development Operations to enhance clinical execution and organizational growth[8].